Nuvilex SG&A Expenses 2010-2024 | PMCB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuvilex sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Nuvilex sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$89B
Takeda Pharmaceutical (TAK)	$47.2B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$22.1B
Summit Therapeutics (SMMT)	$17.8B
Sandoz Group AG (SDZNY)	$17.6B
United Therapeutics (UTHR)	$15.2B
Shionogi (SGIOY)	$13.1B
Neurocrine Biosciences (NBIX)	$12.1B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Corcept Therapeutics (CORT)	$4.4B
Crinetics Pharmaceuticals (CRNX)	$4.2B
Dyne Therapeutics (DYN)	$3.4B
PTC Therapeutics (PTCT)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B